FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of July 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca plans to invest $50bn in the US
22 July
2025
AstraZeneca plans to invest $50 billion in America for medicines
manufacturing and R&D
Investment will support AstraZeneca's ambition to reach $80 billion
revenue by 2030, with 50% generated in the US
Cornerstone of investment is a proposed new multi-billion dollar
drug substance manufacturing centre focused on chronic diseases in
the Commonwealth of Virginia, the Company's largest single
investment in a facility to date
AstraZeneca today announces $50 billion of investment in the United
States by 2030, building on America's global leadership in
medicines manufacturing and R&D. This investment is expected to
create tens of thousands of new, highly skilled direct and indirect
jobs across the country powering growth and delivering next
generation medicines for patients in America and
worldwide.
The cornerstone of this landmark investment is a new multi-billion
dollar US manufacturing facility that will produce drug substances
for the Company's innovative weight management and metabolic
portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and
combination small molecule products. The new state-of-the-art
centre will produce small molecules, peptides and oligonucleotides.
This multi-billion dollar capital investment is in addition to the
$3.5 billion announced in November 2024.
The drug substance facility, planned to be in the Commonwealth of
Virginia, would be AstraZeneca's largest single manufacturing
investment in the world. The facility will leverage AI, automation,
and data analytics to optimise production.
The $50 billion investment across our R&D and manufacturing
footprint in the US over the next five years also
includes:
● Expansion of our R&D facility in
Gaithersburg, Maryland
● State-of-the-art R&D centre in Kendall
Square, Cambridge, Massachusetts
● Next-generation manufacturing facilities for
cell therapy in Rockville, Maryland and Tarzana,
California
● Continuous manufacturing expansion in Mount
Vernon, Indiana
● Specialty manufacturing expansion in
Coppell, Texas
● New sites to supply clinical
trials
● Our growing research and development
investment in novel medicines
Collectively, these investments will help deliver AstraZeneca's
ambition of reaching $80 billion in Total Revenue by 2030, of which
we expect 50% would be generated in the US.
Howard Lutnick, US Secretary of Commerce, said: "For decades
Americans have been reliant on foreign supply of key pharmaceutical
products. President Trump and our nation's new tariff policies are
focused on ending this structural weakness. We are proud that
AstraZeneca has made the decision to bring substantial
pharmaceutical production to our shores. This historic
investment is bringing tens of thousands of jobs to the US and will
ensure medicine sold in our country is produced right
here."
Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to
thank AstraZeneca for choosing Virginia as the cornerstone for this
transformational investment in the United States. This project will
set the standard for the latest technological advancements in
pharmaceutical manufacturing, creating hundreds of highly skilled
jobs and helping further strengthen the nation's domestic supply
chain. Advanced manufacturing is at the heart of Virginia's dynamic
economy, so I am thrilled that AstraZeneca, one of the world's
leading pharmaceutical companies, plans to make their largest
global manufacturing investment here in the
Commonwealth."
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's
announcement underpins our belief in America's innovation in
biopharmaceuticals and our commitment to the millions of patients
who need our medicines in America and globally. It will also
support our ambition to reach $80 billion in revenue by 2030. I
look forward to partnering with Governor Youngkin and his team to
work on our largest single manufacturing investment ever. It
reflects the Commonwealth of Virginia's desire to create highly
skilled jobs in science and technology, and will strengthen the
country's domestic supply chain for medicines."
Notes
AstraZeneca in the US
The US is AstraZeneca's largest market and home to 19 R&D,
manufacturing and commercial sites. We employ more than
18,000 people and support 92,000 jobs overall across the United
States. In 2024 we contributed $5 billion directly to the economy
and created approximately $20 billion worth of overall value for
the American economy.
Today the US represents 42% of our Total Revenue with an ambition
to reach 50% by 2030. This underscores the critical role the US
plays in our ability to deliver on our ambition to launch 20 new
medicines by the end of the decade.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 22 July 2025
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|